Fac-tricarbonyl(pentylcarbonato)(α-diimine)rhenium complexes: One-pot synthesis, characterization, fluorescence studies, and cytotoxic activity against human MDA-MB-231 breast, CCl-227 colon and BxPC-3 pancreatic carcinoma cell lines

Mbagu, Michael K.; Kebulu, Divine N.; Winstead, Angela; Pramanik, Saroj K.; Banerjee, Hirendra Nath; Iwunze, Maurice O.; Wachira, James; Greco, George E.; Haynes, Gregory K.; Sehmer, Amanda; Sarkar, Fazlul H.; Ho, Douglas M.; Pike, Robert D.; Mandal, Santosh K.

doi:10.1016/j.inoche.2012.04.004

Cited by 25 publications

(26 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their anti-proliferative activity reached or even exceeded the one of cisplatin on various human cancer cell lines. 28,30,32,39,40,45,49,51 The cytotoxicity of the compounds generally increased with lipophilicity, 32,33,39,49,51 most probably due to an improved cellular uptake. Re(I) complexes 9 ( Figure 1A) derivatized with a fluorous pendant were the only exception to this trend.…”

Section: -14mentioning

confidence: 99%

Underestimated Potential of Organometallic Rhenium Complexes as Anticancer Agents

2014

View full text Add to dashboard Cite

ABSTRACT:In the recent years, organometallic compounds have become recognized as promising anti-cancer drug candidates. While radioactive 186/188 Re compounds are already used in clinics for cancer treatment, cold Re organometallic compounds have mostly been explored as luminescent probes and photosensitizers in photo-catalysis. However, a growing number of studies have recently revealed the potential of Re organometallic complexes as anticancer agents.Several compounds have displayed cytotoxicity equaling or exceeding that of the well-established anti-cancer drug cisplatin. In this review, we present the currently known Re organometallic complexes that have shown anti-proliferative activity on cancer cell lines. A particular emphasis is placed on their cellular uptake and localization as well as their potential mechanism of action.

show abstract

Section: -14mentioning

confidence: 99%

Underestimated Potential of Organometallic Rhenium Complexes as Anticancer Agents

2014

View full text Add to dashboard Cite

show abstract

“…The structure each compound is depicted in Figure 1. Unlike the rhenium compounds noted above [12–15], the PC -series of compounds exhibit fluorescence [16]. Here we report the cytotoxic effects of the compounds PC1–PC6 on lymphosarcoma, PC-3 prostate, and myeloid leukemia cancer cells and mesangial cells and the DNA-binding study of the compound PC6 using electronic spectroscopy (UV-Visible spectrophotometric titrations).…”

Section: Introductionmentioning

confidence: 78%

“…2,2’-bipyridyl, 2,9-dimethyl-1,10-phenanthroline, and 4,7-diphenyl-1,10-phenanthroline). The crystal structures of PC1 and PC6 were published earlier [16]. The crystallographic data for PC4 will be published elsewhere.…”

Section: Resultsmentioning

confidence: 99%

“…The rhenium compounds PC1–PC6 were synthesized according to the published procedure [16](Mbagu et.al., 2012). In brief, a mixture of Re 2 (CO) 10 and the corresponding polypyridyls in 1:2 mole ratio was refluxed in 1-pentanol while CO 2 was bubbled through the solutions.…”

Section: Methodsmentioning

confidence: 99%

“…For example, several tricarbonylrhenium compounds have been found to be cytotoxic against numerous cancer cell lines [12–15]. In the present study, we synthesized six novel rhenium pentylcarbanato compounds PC1–PC6 [16]. The structure each compound is depicted in Figure 1.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Effect of Novel Rhenium Compounds on Lymphosarcoma, PC-3 Prostate and Myeloid Leukemia Cancer Cell Lines and an Investigation on the DNA Binding Properties of One of these Compounds through Electronic Spectroscopy

Parson

Smith

Krauss

et al. 2013

J Bioproces Biotechniq

View full text Add to dashboard Cite

Despite the tremendous success of cisplatin and other platinum-based anticancer drugs, severe toxicity and resistance to tumors limit their applications. It is believed that the coordination (formation of covalent bond) of the metal (platinum) to the nitrogen bases of DNA cause the ruptures of the cancer as well as normal cells. A search for anticancer drugs with different modes of action resulted in the synthesis of variety of novel compounds. Many of them are in clinical trials now. Recently we synthesized a series of novel rhenium pentylcarbonato compounds (PC1–PC6). The rhenium atom in each compound is coordinated (bonded) to a planar polypyridyl aromatic ligand, thereby forcing each compound to intercalate between the DNA bases. We have investigated the DNA binding properties of one of the PC-series of compounds (PC6) using electronic spectroscopy. The UV absorption titration of PC6 with DNA shows hypochromic effect with concomitant bathochromic shift of the charge transfer band at 290 nm. These results suggest that the compound PC6 binds to DNA through intercalation. It is therefore likely that the other PC-series of compounds will behave in a similar manner. Thus it is expected that these compounds will exhibit negligible or no side effect. We have observed that the PC-series of compounds are strong cytotoxic agents against lymphosarcoma (average GI50 ≈ 2±2.6 µM), PC-3 prostate (average GI50 ≈ 3±2.8 µM) and myeloid leukemia (average GI50 ≈ 3±2.8 µM) cancer cell lines. The average GI50 values of the PC-series of compounds are 2–3 less than the corresponding GI50 values of cisplatin. Also each of the PC-series of compounds exhibits less toxicity than cisplatin in the glomerular mesangial cells.

show abstract

Potential of Metal Complexes for the Treatment of Cancer: Current Update and Future Prospective

Yadav

2021

Chemistry of Biologically Potent Natural Products and Synthetic Compounds

View full text Add to dashboard Cite

Fac-tricarbonyl(pentylcarbonato)(α-diimine)rhenium complexes: One-pot synthesis, characterization, fluorescence studies, and cytotoxic activity against human MDA-MB-231 breast, CCl-227 colon and BxPC-3 pancreatic carcinoma cell lines

Cited by 25 publications

References 7 publications

Underestimated Potential of Organometallic Rhenium Complexes as Anticancer Agents

Underestimated Potential of Organometallic Rhenium Complexes as Anticancer Agents

The Effect of Novel Rhenium Compounds on Lymphosarcoma, PC-3 Prostate and Myeloid Leukemia Cancer Cell Lines and an Investigation on the DNA Binding Properties of One of these Compounds through Electronic Spectroscopy

Potential of Metal Complexes for the Treatment of Cancer: Current Update and Future Prospective

Contact Info

Product

Resources

About